Results 111 to 120 of about 6,463,095 (311)

Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women

open access: yesBMC Gastroenterology, 2019
Background Capecitabine plus bevacizumab (CAP-B) maintenance treatment after 6 cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOXB) has demonstrated clinical activity and failure to compromise quality of life in patients with metastatic ...
Jinsong Su   +7 more
doaj   +1 more source

Overall survival and progression-free survival.

open access: yes, 2018
The overall survival (OS) rate (dotted line) and progression-free survival (PFS) rate (dashed line) of HCC patients with normal liver volume 3. The patient number was 22. The 1-year progression-free survival and overall survival rates were 40.4% and 81.1%
Shih-Chiang Huang (2522638)   +15 more
core   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

open access: yesMolecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce   +11 more
wiley   +1 more source

Multi-institutional validation of a radiomics signature for identification of postoperative progression of soft tissue sarcoma

open access: yesCancer Imaging
Background To develop a magnetic resonance imaging (MRI)-based radiomics signature for evaluating the risk of soft tissue sarcoma (STS) disease progression.
Yuan Yu   +7 more
doaj   +1 more source

Spearman’s correlation between progression free survival and overall survival.

open access: yes, 2015
Spearman’s correlation between progression free survival and overall survival.
Anke H. Maitland-van der Zee (791473)   +4 more
core   +1 more source

Progression‐free survival (PFS) in oncology: caveat emptor! [PDF]

open access: yesBasic & Clinical Pharmacology & Toxicology, 2019
Sarac, Sinan B   +3 more
openaire   +2 more sources

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

open access: yesMolecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience

open access: yesFrontiers in Endocrinology
IntroductionPeptide receptor radionuclide therapy (PRRT) is a treatment option for well-differentiated, somatostatin receptor positive, unresectable or/and metastatic neuroendocrine tumors (NETs).
Vladimir Vukomanovic   +25 more
doaj   +1 more source

Kaplan-Meier curve of overall survival and progression-free survival.

open access: yes, 2016
Kaplan-Meier curve of overall survival and progression-free survival.
Marcelo Bonomi (3216519)   +9 more
core   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

open access: yesMolecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy